<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/"><channel><title>心血管高季刊</title><link/>https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230830120948&amp;utm_medium=rss&amp;utm_campaign=pub med-2&amp;utm_source=Chrome&amp;v=2.17.9.post6+86293ac&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U- NVu8003KrCpq8yLQC -<description>心血管高季刊：PubMed 的最新结果</description><atom:link href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230830120948&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_source=Chrome&amp;v=2.17.9.post6+86293ac&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-" rel="self"></atom:link><docs> http://www.rssboard.org/rss-specification</docs><generator> PubMed RSS 源 (2.17.9.post6+86293ac)</generator><language> zh</language><lastbuilddate> 2023 年 8 月 30 日星期三 16:09:50 +0000</lastbuilddate><pubDate> Wed, 30 Aug 2023 06:00:00 -0400</pubDate><ttl> 120</ttl><item><title>动脉粥样硬化蛋白质组图谱：蛋白多糖对性别差异、斑块表型和结果的贡献</title><link/>https://pubmed.ncbi.nlm.nih.gov/37646165/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230830120948&amp;v=2.17.9.post6+86293ac<description>结论：斑块蛋白质组学重新定义了具有不同结果的临床相关患者群体，确定了未来心血管事件风险升高的男性和女性患者亚组。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Circ Res. 2023 年 8 月 30 日。doi：10.1161/CIRCRESAHA.123.322590。印刷前在线。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">背景：利用蛋白质组学，我们的目标是揭示人类动脉粥样硬化病变的分子类型，并研究它们与组织学、影像学和心血管结果的关系。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">方法：从 120 名患者身上采集了 219 份颈动脉内膜切除术样本。采用序贯蛋白质提取方案与多重发现蛋白质组学相结合。为了关注细胞外蛋白质，采用平行反应监测进行靶向蛋白质组学。蛋白质组学特征与本体整合、单细胞和空间 RNA 测序数据，并在 Athero-Express Biobank 研究的 200 名患者中进行了验证。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结果：这项广泛的蛋白质组学分析确定了斑块炎症和钙化特征，这些特征与靶向蛋白质组学、胎球蛋白-A、骨桥蛋白和γ-羧化蛋白呈负相关并得到验证。蛋白质组学数据还揭示了动脉粥样硬化中存在大聚集蛋白聚糖的性别差异。多功能蛋白聚糖和聚集蛋白聚糖在女性中更为丰富，并与雌二醇水平呈负相关。数据将炎症特征主要归因于中性粒细胞和巨噬细胞，将钙化和性别特征归因于平滑肌细胞，但某些不表达但保留的血浆蛋白除外斑块中，如胎球蛋白-A。根据蛋白质组学数据识别 4 种不同的斑块表型。4 种关键蛋白质（钙调蛋白、蛋白质 C、丝氨酸蛋白酶抑制剂 H1 和多功能蛋白聚糖）的蛋白质特征预测未来心血管死亡率，曲线下面积为在发现和验证队列中分别为 75% 和 67.5%，超过了影像学和组织学的预后表现。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结论：斑块蛋白质组学重新定义了具有不同结果的临床相关患者群体，确定了未来心血管事件风险升高的男性和女性患者亚组。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37646165/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230830120948&v=2.17.9.post6+86293ac">37646165</a> | DOI： <a href=https://doi.org/10.1161/CIRCRESAHA.123.322590>10.1161/CIRCRESAHA.123.322590</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37646165</guid><pubDate> Wed, 30 Aug 2023 06:00:00 -0400</pubDate><dc:creator>康斯坦丁诺斯·塞奥菲拉托斯</dc:creator><dc:creator>斯特凡·斯托伊科维奇</dc:creator><dc:creator>玛丽亚·哈斯曼</dc:creator><dc:creator>桑德·W·范德兰</dc:creator><dc:creator>费欣·拜格</dc:creator><dc:creator>哈维尔·巴拉洛布雷·巴雷罗</dc:creator><dc:creator>卢卡斯·施密特</dc:creator><dc:creator>尹思琪</dc:creator><dc:creator>尹晓科</dc:creator><dc:creator>肖恩·伯纳普</dc:creator><dc:creator>巴瓦纳·辛格</dc:creator><dc:creator>裘德·波帕姆</dc:creator><dc:creator>奥莱西亚·哈科特</dc:creator><dc:creator>斯蒂芬妮·坎普夫</dc:creator><dc:creator>玛雅·卡琳娜·纳肯霍斯特</dc:creator><dc:creator>安德烈亚斯·斯特拉斯尔</dc:creator><dc:creator>克里斯蒂安·罗意威</dc:creator><dc:creator>斯维特拉娜·德米亚涅茨</dc:creator><dc:creator>克里斯托夫·纽迈尔</dc:creator><dc:creator>马丁·比尔班</dc:creator><dc:creator>克里斯蒂安·亨斯滕伯格</dc:creator><dc:creator>库尔特·胡贝尔</dc:creator><dc:creator>杰拉德·帕斯特坎普</dc:creator><dc:creator>约翰·沃伊塔</dc:creator><dc:creator>曼努埃尔·迈尔</dc:creator><dc:date>2023-08-30</dc:date><dc:source>流通研究</dc:source><dc:title>动脉粥样硬化蛋白质组图谱：蛋白多糖对性别差异、斑块表型和结果的贡献</dc:title><dc:identifier>下午：37646165</dc:identifier><dc:identifier> doi:10.1161/CIRCRESAHA.123.322590</dc:identifier></item><item><title>健康信息收集、共享和使用原则：美国心脏协会的政策声明</title><link/>https://pubmed.ncbi.nlm.nih.gov/37646159/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230830120948&amp;v=2.17.9.post6+86293ac<description>电子健康记录的发展，加上数据管理和分析技术的进步，越来越多地实现了数据共享和协调。健康相关和健康代理信息分析的进步已经加速了研究发现并改善了患者护理。心脏协会政策声明讨论了广泛的数据共享如何通过提供数据来开发、测试和基准测试来推动进步...... </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>流通</b>。2023 年 8 月 30 日。doi：10.1161/CIR.0000000000001173。印刷前在线。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">电子健康记录的发展，加上数据管理和分析技术的进步，越来越多地实现了数据共享和协调。健康相关和健康代理信息分析的进步已经加速了研究发现并改善了患者护理。心脏协会政策声明讨论了广泛的数据共享如何通过提供数据来开发、测试和基准测试创新方法、可扩展的见解以及数据存储和工作流程的潜在新范式，从而成为进步的推动力。一些健康数据的敏感性，关于公平性的考虑历史上被排除在外的社区的参与，以及试图管理行为的复杂的法律交叉。因此，数据共享原则对于广泛的实体是必要的，包括收集健康信息的各方、资助者。本政策声明概述了一些关键的公平和原则与健康数据共享和负责任的管理相关的法律背景。然后阐明了指导美国心脏协会参与与数据收集、共享和使用相关的公共政策的原则，以继续为其整个研究企业的工作提供信息，以及具体的建议如何在政策环境中应用这些原则的示例：以尊重患者和研究参与者的方式使用或重复使用健康信息，在风险和潜在利益方面具有公平的影响，并有益于广泛和人口多样化美国的社区。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37646159/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230830120948&v=2.17.9.post6+86293ac">37646159</a> | DOI： <a href=https://doi.org/10.1161/CIR.0000000000001173>10.1161/CIR.0000000000001173</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37646159</guid><pubDate> Wed, 30 Aug 2023 06:00:00 -0400</pubDate><dc:creator>凯特·斯佩克特-巴格达迪</dc:creator><dc:creator>安东尼斯·阿蒙达斯</dc:creator><dc:creator>里玛·阿诺特</dc:creator><dc:creator>詹妮弗·L·霍尔</dc:creator><dc:creator>布鲁克·耶格尔·麦克斯温</dc:creator><dc:creator>约书亚·W·诺尔斯</dc:creator><dc:creator>W·尼克尔森·普莱斯</dc:creator><dc:creator>丹达·拉瓦特</dc:creator><dc:creator>芭芭拉·里格尔</dc:creator><dc:creator>王翠西</dc:creator><dc:creator>——凯文·威利</dc:creator><dc:creator>钟米娜</dc:creator><dc:creator>美国心脏协会倡导协调委员会</dc:creator><dc:date>2023-08-30</dc:date><dc:source>循环</dc:source><dc:title>健康信息收集、共享和使用原则：美国心脏协会的政策声明</dc:title><dc:identifier>下午：37646159</dc:identifier><dc:identifier>号码：10.1161/CIR.0000000000001173</dc:identifier></item><item><title> SIRT3 通过去乙酰化 Frataxin 调节凋亡心肌细胞的清除</title><link/>https://pubmed.ncbi.nlm.nih.gov/37646156/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230830120948&amp;v=2.17.9.post6+86293ac<description>结论：SIRT3-FXN 轴具有通过增加巨噬细胞胞吞作用和抗炎活性来解决心脏炎症的潜力。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Circ Res. 2023 年 8 月 30 日。doi：10.1161/CIRCRESAHA.123.323160。印刷前在线。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">背景：胞吞作用是巨噬细胞的一种活性，对于高血压炎症的解决至关重要。巨噬细胞协调胞吞作用和内化凋亡心肌细胞的确切机制仍不清楚。本研究的目的是确定 SIRT3 (sirtuin-3) 是否细胞凋亡过程中凋亡心肌细胞吞噬和抗炎反应所必需的。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">方法：我们制备了髓系 SIRT3 敲除小鼠和携带乙酰化缺陷型赖氨酸至精氨酸 K189R 突变（FXN <sup>K189R</sup> ）的敲入小鼠。给小鼠注射 Ang II（血管紧张素 II）7 天。我们分析了心脏巨噬细胞的线粒体铁。体内和体外的水平、胞吞活性和表型。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结果：我们发现 SIRT3 缺乏加剧了 Ang II 诱导的胞吞作用受体 MerTK（c-Mer 酪氨酸激酶）的下调和促炎细胞因子的产生，并伴随着心脏巨噬细胞中线粒体铁稳态的破坏。定量乙酰组分析显示，SIRT3 去乙酰化 FXN（frataxin） ) 在赖氨酸 189 处。Ang II 减弱 SIRT3 活性并增强 FXN K189 的乙酰化水平。乙酰化 FXN 进一步减少 ISC（铁硫簇）的合成，导致线粒体铁积累。凋亡心肌细胞的吞噬内化增加了肌红蛋白含量，并且衍生的铁离子促进线粒体铁超载和脂质过氧化。铁螯合剂去铁胺提高了 MerTK 和胞吞作用的水平，从而减弱了促炎巨噬细胞的活化。FXN <sup>K189R</sup>小鼠表现出改善的巨噬细胞胞吞作用，减少了心脏炎症，并抑制了心脏纤维化。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结论：SIRT3-FXN 轴具有通过增加巨噬细胞胞吞作用和抗炎活性来解决心脏炎症的潜力。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37646156/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230830120948&v=2.17.9.post6+86293ac">37646156</a> | DOI： <a href=https://doi.org/10.1161/CIRCRESAHA.123.323160>10.1161/CIRCRESAHA.123.323160</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37646156</guid><pubDate> Wed, 30 Aug 2023 06:00:00 -0400</pubDate><dc:creator>高靖</dc:creator><dc:creator>黄成林</dc:creator><dc:creator>孔令辉</dc:creator><dc:creator>周武刚</dc:creator><dc:creator>孙孟伟</dc:creator><dc:creator>童薇</dc:creator><dc:creator>沉伟丽</dc:creator><dc:date>2023-08-30</dc:date><dc:source>流通研究</dc:source><dc:title>SIRT3 通过去乙酰化 Frataxin 调节凋亡心肌细胞的清除</dc:title><dc:identifier>下午：37646156</dc:identifier><dc:identifier> doi:10.1161/CIRCRESAHA.123.323160</dc:identifier></item><item><title>昼夜节律医学：心脏护理的关键策略</title><link/>https://pubmed.ncbi.nlm.nih.gov/37644115/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230830120948&amp;v=2.17.9.post6+86293ac<description>没有摘要</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Nat Rev Cardiol.2023 年 8 月 29 日。doi：10.1038/s41569-023-00925-8。印刷前在线。</p><p><b>无摘要</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37644115/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230830120948&v=2.17.9.post6+86293ac">37644115</a> | DOI： <a href=https://doi.org/10.1038/s41569-023-00925-8>10.1038/s41569-023-00925-8</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37644115</guid><pubDate> Tue, 29 Aug 2023 06:00:00 -0400</pubDate><dc:creator> ——迈克尔·J·索尔</dc:creator><dc:creator>塔米·马蒂诺</dc:creator><dc:date>2023-08-29</dc:date><dc:source> 《自然》评论、心脏病学</dc:source><dc:title>昼夜节律医学：心脏护理的关键策略</dc:title><dc:identifier>下午：37644115</dc:identifier><dc:identifier> doi:10.1038/s41569-023-00925-8</dc:identifier></item><item><title>非甾体盐皮质激素受体拮抗剂治疗心力衰竭</title><link/>https://pubmed.ncbi.nlm.nih.gov/37644114/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230830120948&amp;v=2.17.9.post6+86293ac<description>没有摘要</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Nat Rev Cardiol。2023 年 8 月 29 日。doi：10.1038/s41569-023-00922-x。印刷前在线。</p><p><b>无摘要</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37644114/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230830120948&v=2.17.9.post6+86293ac">37644114</a> | DOI： <a href=https://doi.org/10.1038/s41569-023-00922-x>10.1038/s41569-023-00922-x</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37644114</guid><pubDate> Tue, 29 Aug 2023 06:00:00 -0400</pubDate><dc:creator>格拉西莫斯·菲利帕托斯</dc:creator><dc:creator>迪米特里奥斯·法马基斯</dc:creator><dc:date>2023-08-29</dc:date><dc:source> 《自然》评论、心脏病学</dc:source><dc:title>非甾体盐皮质激素受体拮抗剂治疗心力衰竭</dc:title><dc:identifier>下午：37644114</dc:identifier><dc:identifier> doi:10.1038/s41569-023-00922-x</dc:identifier></item><item><title> DDM1 对组蛋白 H3 变体的染色质重塑是 DNA 甲基化表观遗传的基础</title><link/>https://pubmed.ncbi.nlm.nih.gov/37643610/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230830120948&amp;v=2.17.9.post6+86293ac<description>核小体会阻止 DNA 甲基转移酶的进入，除非它们通过 DNA 甲基化 1 的减少 (DDM1^(LSH)^(^(/)HELLS)) 进行重塑，这是一种表观遗传遗传的类似 Snf2 的主调节因子。我们表明，DDM1 促进H3.1 产生组蛋白变体 H3.3。在 ddm1 突变体中，DNA 甲基化因 H3.3 伴侣 HIRA 的丢失而部分恢复，而 H3.1 伴侣 CAF-1 变得至关重要。单颗粒冷冻电镜结构3.2 Å 的 DDM1 与变异核小体揭示了...... </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> <b>Cell</b> . 2023 年 8 月 24 日：S0092-8674(23)00855-3. doi: 10.1016/j.cell.2023.08.001. 印刷前在线。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">核小体会阻止 DNA 甲基转移酶的进入，除非它们通过 DNA 甲基化 1 的减少 (DDM1 <sup>LSH</sup> <sup><sup>/</sup> HELLS</sup> ) 进行重塑，DNA 甲基化 1 是表观遗传的 Snf2 样主调节因子。我们表明，DDM1 促进组蛋白变体 H3.3 被 H3.1 取代在 ddm1 突变体中，DNA 甲基化因 H3.3 伴侣蛋白 HIRA 的丢失而部分恢复，而 H3.1 伴侣蛋白 CAF-1 变得至关重要。DDM1 3.2 Å 处的单颗粒冷冻电镜结构与变异核小体揭示了接合组蛋白 H3.3 靠近组装所需的残基以及未修饰的 H4 尾。N 端自抑制结构域抑制活性，而解旋酶结构域中的二硫键支持活性。DDM1 在组装过程中与 H3.1 和 H3.3 共定位细胞周期，以及 DNA 甲基转移酶 MET1 <sup>Dnmt1</sup> ，但被 H4K16 乙酰化阻断。雄性种系 H3.3 变体 MGH3/HTR10 对 DDM1 的重塑具有抵抗力，并充当精子细胞中表观遗传的占位核小体。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37643610/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230830120948&v=2.17.9.post6+86293ac">37643610</a> | DOI： <a href=https://doi.org/10.1016/j.cell.2023.08.001>10.1016/j.cell.2023.08.001</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37643610</guid><pubDate> Tue, 29 Aug 2023 06:00:00 -0400</pubDate><dc:creator>李承祖</dc:creator><dc:creator>德克斯特·W·亚当斯</dc:creator><dc:creator>乔纳森·J·伊普萨罗</dc:creator><dc:creator>——乔纳森·卡恩</dc:creator><dc:creator>贾森·林恩</dc:creator><dc:creator>金贤秀</dc:creator><dc:creator>本杰明·贝鲁贝</dc:creator><dc:creator>维多利亚·梅杰</dc:creator><dc:creator>约瑟夫·P·卡拉科</dc:creator><dc:creator>尚塔尔·勒布朗</dc:creator><dc:creator>索娜莉·巴塔查吉</dc:creator><dc:creator>乌玛玛赫斯瓦里·拉穆</dc:creator><dc:creator>丹尼尔·格里马内利</dc:creator><dc:creator>雅尼克·雅各布</dc:creator><dc:creator>菲利普·沃伊特</dc:creator><dc:creator>利莫尔·约书亚·托尔</dc:creator><dc:creator>罗伯特·马丁森</dc:creator><dc:date>2023-08-29</dc:date><dc:source>细胞</dc:source><dc:title>DDM1 对组蛋白 H3 变体的染色质重塑是 DNA 甲基化表观遗传的基础</dc:title><dc:identifier>下午：37643610</dc:identifier><dc:identifier> doi:10.1016/j.cell.2023.08.001</dc:identifier></item><item><title>开始使用盐皮质激素拮抗剂治疗射血分数降低的长期心力衰竭：迟做总比不做好？</title><link/> https://pubmed.ncbi.nlm.nih.gov/37642609/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230830120948&amp;v=2.17.9.post6+86293ac<description>没有摘要</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> J Am Coll Cardiol。2023 年 8 月 1 日：S0735-1097(23)06074-6。doi：10.1016/j.jacc.2023.06.022。印刷前在线。</p><p><b>无摘要</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37642609/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230830120948&v=2.17.9.post6+86293ac">37642609</a> | DOI： <a href=https://doi.org/10.1016/j.jacc.2023.06.022>10.1016/j.jacc.2023.06.022</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37642609</guid><pubDate> Tue, 29 Aug 2023 06:00:00 -0400</pubDate><dc:creator> ——安德鲁·J·索尔</dc:creator><dc:creator>夏朱迪思</dc:creator><dc:date>2023-08-29</dc:date><dc:source>美国心脏病学会杂志</dc:source><dc:title>开始使用盐皮质激素拮抗剂治疗射血分数降低的长期心力衰竭：迟做总比不做好？</dc:title><dc:identifier>下午：37642609</dc:identifier><dc:identifier> doi:10.1016/j.jacc.2023.06.022</dc:identifier></item><item><title>射血分数降低的心力衰竭患者盐皮质激素拮抗剂的利用不足</title><link/>https://pubmed.ncbi.nlm.nih.gov/37642608/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230830120948&amp;v=2.17.9.post6+86293ac<description>结论：长期 HFrEF 患者的临床状态较差，事件发生率较高，但无论 HFrEF 持续时间如何，依普利农的益处都是一致的。（NYHA II 级心力衰竭患者使用依普利酮或安慰剂治疗时的结果比较除了标准心力衰竭药物 [EMPHASIS-HF]；NCT00232180）。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> J Am Coll Cardiol。2023 年 8 月 1 日：S0735-1097(23)06073-4。doi：10.1016/j.jacc.2023.06.021。印刷前在线。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">背景：尚不清楚盐皮质激素受体拮抗剂的功效和安全性如何根据射血分数降低的心力衰竭（HFrEF）的持续时间而变化。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">目的：在本研究中，我们试图根据 HFrEF 的持续时间评估依普利农的安全性和有效性。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">方法：在 EMPHASIS-HF 试验中，根据 HFrEF 持续时间创建 3 个患者组：&lt;1 年、1 至 &lt;5 年和≥5 年。主要结局是心力衰竭 (HF) 住院或心血管死亡的复合结果. 结果根据预先指定的预后变量进行调整，并使用 Cox 回归模型进行检查。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结果：每组患者人数分别为：975 例，&lt;1 岁；769 例，1 至&lt;5 岁；988 例，≥5 岁。长期心力衰竭患者年龄较大，更常见心血管和非心血管合并症。主要结局的比率（每 100 人年）随着 HFrEF 持续时间的增加而增加：&lt;1 年为 9.8 (95% CI: 8.4-11.4)，1 至 &lt;5 年为 13.5 (95% CI: 11.6-15.7)，17.6 (95% CI: 15.6-19.8) ≥5 年。依普利农的益处在整个 HF 持续时间内是一致的：主要结局的 HR 为 0.57 (95% CI: 0.42-0.79)，&lt;1 年为 0.81 (95% CI) : 0.60-1.10) 对于 1 到 &lt;5 年，和 0.61 (95% CI: 0.48-0.78) 对于 ≥5 年；P<sub>相互作用</sub>= 0.24。主要结局的治疗为 14 对于 &lt;1 年，13 对于 1 到 &lt; 5 年，持续时间≥5 年的为 10 年。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结论：长期 HFrEF 患者的临床状态较差，事件发生率较高，但无论 HFrEF 持续时间如何，依普利农的益处都是一致的。（NYHA II 级心力衰竭患者使用依普利酮或安慰剂治疗时的结果比较除了标准心力衰竭药物 [EMPHASIS-HF]；NCT00232180）。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37642608/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230830120948&v=2.17.9.post6+86293ac">37642608</a> | DOI： <a href=https://doi.org/10.1016/j.jacc.2023.06.021>10.1016/j.jacc.2023.06.021</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37642608</guid><pubDate> Tue, 29 Aug 2023 06:00:00 -0400</pubDate><dc:creator>松本真吾</dc:creator><dc:creator>近藤彻</dc:creator><dc:creator>帕迪普·S·琼德</dc:creator><dc:creator>罗斯·T·坎贝尔</dc:creator><dc:creator>卡尔·斯韦德伯格</dc:creator><dc:creator>德克·J·范·维尔德豪森</dc:creator><dc:creator>斯图尔特·J·波科克</dc:creator><dc:creator>伯特伦·皮特</dc:creator><dc:creator>Faiez Zannad更多</dc:creator><dc:creator>约翰·JV·麦克默里</dc:creator><dc:date>2023-08-29</dc:date><dc:source>美国心脏病学会杂志</dc:source><dc:title>射血分数降低的心力衰竭患者盐皮质激素拮抗剂的利用不足</dc:title><dc:identifier>下午：37642608</dc:identifier><dc:identifier> doi:10.1016/j.jacc.2023.06.021</dc:identifier></item><item><title> ESC 心血管再生和修复医学工作组</title><link/>https://pubmed.ncbi.nlm.nih.gov/37642557/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230830120948&amp;v=2.17.9.post6+86293ac<description>没有摘要</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Eur Heart J. 2023 年 8 月 29 日：ehad538。doi：10.1093/eurheartj/ehad538。印刷前在线。</p><p><b>无摘要</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37642557/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230830120948&v=2.17.9.post6+86293ac">37642557</a> | DOI： <a href=https://doi.org/10.1093/eurheartj/ehad538>10.1093/eurheartj/ehad538</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37642557</guid><pubDate> Tue, 29 Aug 2023 06:00:00 -0400</pubDate><dc:creator>朱利奥·庞皮利奥</dc:creator><dc:creator>里卡多·桑斯·鲁伊斯</dc:creator><dc:creator>约斯特 PG 斯鲁伊特</dc:creator><dc:creator>斯特凡·詹森斯</dc:creator><dc:date>2023-08-29</dc:date><dc:source>欧洲心脏杂志</dc:source><dc:title>ESC 心血管再生和修复医学工作组</dc:title><dc:identifier>下午：37642557</dc:identifier><dc:identifier> doi:10.1093/eurheartj/ehad538</dc:identifier></item><item><title>将商业广告的原则融入心血管健康促进工作中</title><link/>https://pubmed.ncbi.nlm.nih.gov/37642214/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230830120948&amp;v=2.17.9.post6+86293ac<description>没有摘要</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Eur Heart J. 2023 年 8 月 29 日：ehad537。doi：10.1093/eurheartj/ehad537。印刷前在线。</p><p><b>无摘要</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37642214/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230830120948&v=2.17.9.post6+86293ac">37642214</a> | DOI： <a href=https://doi.org/10.1093/eurheartj/ehad537>10.1093/eurheartj/ehad537</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37642214</guid><pubDate> Tue, 29 Aug 2023 06:00:00 -0400</pubDate><dc:creator>大卫·JT·坎贝尔</dc:creator><dc:creator>Raj Pannu更多</dc:creator><dc:creator>布雷登·J·曼斯</dc:creator><dc:date>2023-08-29</dc:date><dc:source>欧洲心脏杂志</dc:source><dc:title>将商业广告的原则融入心血管健康促进工作中</dc:title><dc:identifier>下午：37642214</dc:identifier><dc:identifier> doi:10.1093/eurheartj/ehad537</dc:identifier></item><item><title> S14-磷酸化 RPN6 通过 PKA 介导蛋白酶体激活并减轻蛋白病</title><link/>https://pubmed.ncbi.nlm.nih.gov/37641975/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230830120948&amp;v=2.17.9.post6+86293ac<description>结论：本研究在动物中证实 pS14-Rpn6 通过 PKA 介导 26S 蛋白酶体的激活，并且减少的 pS14-Rpn6 是心脏蛋白病的关键致病因素，从而确定了减少心脏蛋白毒性的新治疗靶点。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Circ Res. 2023 年 8 月 29 日。doi：10.1161/CIRCRESAHA.123.322887。印刷前在线。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">背景：更好地了解蛋白酶体活性的调节有助于寻找新的治疗策略。细胞培养研究表明，cAMP依赖性PKA（蛋白激酶A）通过pS14-Rpn6（丝氨酸14磷酸化Rpn6）激活26S蛋白酶体，但这一发现及其生理意义仍有待在体内确定。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">方法：创建 Rpn6 Ser14 突变为 Ala (S14A [Rpn6/Psmd11 <sup>S14A</sup> ]) 或 Asp (S14D) 的雄性和雌性小鼠，分别阻断或模拟 pS14-Rpn6，并与源自它们的细胞一起使用。泛素-蛋白酶体系统功能通过 GFPdgn 报告小鼠和蛋白酶体活性测定进行评估。在过度表达错误折叠蛋白 R120G-CryAB (R120G) 的小鼠和心肌细胞中测试了 S14A 和 S14D 对蛋白毒性的影响。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结果：PKA 激活增加了野生型而非 S14A 胚胎成纤维细胞（小鼠胚胎成纤维细胞）、成年心肌细胞和小鼠心脏中的 pS14-Rpn6 和 26S 蛋白酶体活性。S14D 心肌和成年小鼠心肌细胞中的基础 26S 蛋白酶体活性显着高于对照组。与野生型对应物相比，S14D::GFPdgn 小鼠显示出比 GFPdgn 小鼠更低的心肌 GFPdgn 蛋白，但不显示 mRNA 水平。在 R120G 小鼠（心脏蛋白毒性的经典模型）中，与非转基因同窝小鼠相比，基础心肌 pS14-Rpn6 显着降低。与野生型新生儿心肌细胞相比，S14D 新生心肌细胞对 R120G 的蛋白酶体降解速度显着加快。与 R120G 小鼠相比，S14D/S14D::R120G 小鼠的心肌蛋白酶体活性显着增强，总泛素和 K48 连接泛素缀合物以及异常泛素缀合物水平较低。 CryAB蛋白聚集，胎儿基因再激活减少，心脏肥大，心脏功能障碍延迟。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结论：本研究在动物中证实 pS14-Rpn6 通过 PKA 介导 26S 蛋白酶体的激活，并且减少的 pS14-Rpn6 是心脏蛋白病的关键致病因素，从而确定了减少心脏蛋白毒性的新治疗靶点。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37641975/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230830120948&v=2.17.9.post6+86293ac">37641975</a> | DOI： <a href=https://doi.org/10.1161/CIRCRESAHA.123.322887>10.1161/CIRCRESAHA.123.322887</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37641975</guid><pubDate> Tue, 29 Aug 2023 06:00:00 -0400</pubDate><dc:creator>杨柳青</dc:creator><dc:creator>尼尔玛·帕拉茹利</dc:creator><dc:creator>吴鹏龙</dc:creator><dc:creator>刘金宝</dc:creator><dc:creator>王学军更多</dc:creator><dc:date>2023-08-29</dc:date><dc:source>流通研究</dc:source><dc:title>S14-磷酸化 RPN6 通过 PKA 介导蛋白酶体激活并减轻蛋白病</dc:title><dc:identifier>下午：37641975</dc:identifier><dc:identifier> doi:10.1161/CIRCRESAHA.123.322887</dc:identifier></item><item><title>罕见变异遗传学和扩张型心肌病严重程度：DCM 精准医学研究</title><link/>https://pubmed.ncbi.nlm.nih.gov/37641966/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230830120948&amp;v=2.17.9.post6+86293ac<description>结论：与较不严重的 DCM 个体相比，晚期 DCM 与被判定为致病性或可能致病性的 DCM 基因中罕见变异的几率较高相关。这一发现可能有助于评估 DCM 患者及其高危患者管理中的结果风险。家庭成员。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>流通</b>。2023 年 8 月 29 日。doi：10.1161/CIRCULATIONAHA.123.064847。印刷前在线。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">背景：扩张型心肌病 (DCM) 可导致晚期疾病，本文定义为需要耐用的左心室辅助装置或心脏移植 (LVAD/HT)。已知 DCM 具有遗传基础，但罕见变异遗传学与高级DCM尚未研究。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">方法：我们分析了 2016 年至 2021 年美国多中心 DCM 精准医学研究中入组患者的临床和基因序列数据，该研究是一个地域多样、多种族、多民族的队列。临床评估包括标准化患者访谈和病历查询表。DCM 严重程度被分为 3 组：患有 LVAD/HT 的晚期疾病患者；仅植入式心律转复除颤器 (ICD) 的患者；或无 ICD 或 LVAD/HT 的患者。36 个 DCM 基因中的罕见变异被分类为致病性或可能致病性或我们考虑的混杂因素包括人口特征、生活方式因素、获得护理的机会、DCM 持续时间和合并症。使用具有广义 Logit 关联的多项模型评估 DCM 严重程度与罕见变异遗传结果之间的粗略和调整关联。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结果：患者的平均 (SD) 年龄为 51.9 (13.6) 岁；42% 为非洲血统，56% 为欧洲血统，44% 为女性。1198 名患者中，347 名患有 LVAD/HT，511 名患有 ICD对于 LVAD/HT、仅 ICD 或两者都没有的患者，具有致病性或可能致病性变异的患者比例分别为 26.2%、15.9% 和 15.0%。那些没有 LVAD/HT 或 ICD 的患者具有与 DCM 相关的致病性或可能致病性罕见变异（比值比，2.3 [95% CI，1.5–3.6]）。相关性并没有因血统而异。罕见变异的遗传发现在患有 DCM 的患者之间相似。带 ICD 的 DCM 和不带 LVAD/HT 或 ICD 的 DCM。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结论：与较不严重的 DCM 个体相比，晚期 DCM 与被判定为致病性或可能致病性的 DCM 基因中罕见变异的几率较高相关。这一发现可能有助于评估 DCM 患者及其高危患者管理中的结果风险。家庭成员。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">注册：网址：https://www. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">临床试验：gov；唯一标识符：NCT03037632。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37641966/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230830120948&v=2.17.9.post6+86293ac">37641966</a> | DOI： <a href=https://doi.org/10.1161/CIRCULATIONAHA.123.064847>10.1161 / CIRCULATIONAHA.123.064847</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37641966</guid><pubDate> Tue, 29 Aug 2023 06:00:00 -0400</pubDate><dc:creator>马克·霍夫迈尔</dc:creator><dc:creator>加里·J·哈斯</dc:creator><dc:creator>伊丽莎白乔丹</dc:creator><dc:creator>曹金文</dc:creator><dc:creator>埃文·克兰斯多夫</dc:creator><dc:creator>——格雷戈里·A·埃瓦尔德</dc:creator><dc:creator>阿兰娜·莫里斯</dc:creator><dc:creator>安贾利·欧文斯</dc:creator><dc:creator>布赖恩·洛斯</dc:creator><dc:creator>道格拉斯·斯托勒</dc:creator><dc:creator>WH 邓伟逊</dc:creator><dc:creator>索尼娅·加尔格</dc:creator><dc:creator>巴里·特拉亨伯格</dc:creator><dc:creator>帕拉克·沙阿</dc:creator><dc:creator>萨尔皮 V 庞布基安</dc:creator><dc:creator>南希·K·斯威策</dc:creator><dc:creator>——马修·T·惠勒</dc:creator><dc:creator>简·E·威尔科克斯</dc:creator><dc:creator>——斯图尔特·卡茨</dc:creator><dc:creator>斯蒂芬·潘</dc:creator><dc:creator>哈维尔希门尼斯</dc:creator><dc:creator>弗兰克·斯马特</dc:creator><dc:creator>——王杰西卡</dc:creator><dc:creator>斯蒂芬·戈特利布</dc:creator><dc:creator>丹尼尔·P·贾吉</dc:creator><dc:creator>查尔斯·K·摩尔</dc:creator><dc:creator>——戈登·S·哈金斯</dc:creator><dc:creator>丹尼尔·D·金纳蒙</dc:creator><dc:creator>倪瀚宇</dc:creator><dc:creator>雷·E·赫什伯格</dc:creator><dc:creator>DCM联盟的DCM精准医学研究</dc:creator><dc:date>2023-08-29</dc:date><dc:source>循环</dc:source><dc:title>罕见变异遗传学和扩张型心肌病严重程度：DCM 精准医学研究</dc:title><dc:identifier>下午：37641966</dc:identifier><dc:identifier> doi:10.1161/循环AHA.123.064847</dc:identifier></item><item><title>运动期间心脏迷走神经活动增加，以增强冠状动脉血流量</title><link/>https://pubmed.ncbi.nlm.nih.gov/37641938/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230830120948&amp;v=2.17.9.post6+86293ac<description>结论：我们的研究表明，心脏迷走神经活动实际上会增加，对于运动期间维持心脏功能至关重要。此外，我们的研究结果表明，运动期间冠状动脉血流的动态调节是由 VIP 介导的。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Circ Res. 2023 年 8 月 29 日。doi：10.1161/CIRCRESAHA.123.323017。印刷前在线。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">背景：在讨论运动过程中心脏的自主控制时，经常使用“迷走神经完全撤退”这个词。然而，最近的研究对这一假设提出了挑战。我们假设心脏迷走神经活动在运动过程中增加，并通过乙酰胆碱以外的递质维持心脏功能。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">方法：对清醒的成年羊进行全身跑步机运动时，长期直接记录心脏迷走神经活动、心输出量、冠状动脉血流量和心率。用亲脂性示踪染料证实左心迷走神经分支的心脏神经支配。 DiO）。用乙酰胆碱药物阻断剂（阿托品，250 mg）、VIP（血管活性肠肽；[4Cl-D-Phe6，Leu17] VIP 25 µg）或盐水对照对绵羊进行锻炼，在不同的日子随机进行。左心脏迷走神经分支被去神经支配。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结果：在主要心脏神经节丛以及与冠状动脉相关的脂肪垫内可以看到来自心脏迷走神经分支的神经支配。直接记录的心脏迷走神经活动在运动期间增加。左心脏迷走神经分支去神经减弱了冠状动脉的最大变化血流量（最大运动，对照：63.5±5.9 mL/min，n=8；心脏迷走神经去神经：32.7±5.6 mL/min，n=6， <i>P=</i> 2.5×10 <sup>-</sup> <sup>7</sup> ）、心输出量和心率阿托品不会影响运动期间的任何心脏参数，但 VIP 拮抗作用显着降低运动期间的冠状动脉血流量，达到与迷走神经去神经术相似的水平。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结论：我们的研究表明，心脏迷走神经活动实际上会增加，对于运动期间维持心脏功能至关重要。此外，我们的研究结果表明，运动期间冠状动脉血流的动态调节是由 VIP 介导的。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37641938/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230830120948&v=2.17.9.post6+86293ac">37641938</a> | DOI： <a href=https://doi.org/10.1161/CIRCRESAHA.123.323017>10.1161/CIRCRESAHA.123.323017</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37641938</guid><pubDate> Tue, 29 Aug 2023 06:00:00 -0400</pubDate><dc:creator>朱莉娅·香克斯</dc:creator><dc:creator>姆里杜拉·帕钦</dc:creator><dc:creator>张伟华</dc:creator><dc:creator>宾杜·乔治更多</dc:creator><dc:creator>罗希特·拉姆钱德拉</dc:creator><dc:date>2023-08-29</dc:date><dc:source>流通研究</dc:source><dc:title>运动期间心脏迷走神经活动增加，以增强冠状动脉血流量</dc:title><dc:identifier>下午：37641938</dc:identifier><dc:identifier> doi:10.1161/CIRCRESAHA.123.323017</dc:identifier></item><item><title>中性粒细胞血运重建需要 TNFα 激活 CCR6 和 CCL20</title><link/> https://pubmed.ncbi.nlm.nih.gov/37641931/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230830120948&amp;v=2.17.9.post6+86293ac<description>结论：我们证明，通过 TNFα 对 CCL20-CCR6 轴进行位点特异性激活，可将表达促血管生成 VEGFA 的中性粒细胞募集到缺血性损伤部位，从而启动肌肉组织血运重建。这些发现为组织血运重建提供了一个有吸引力的选择，特别是在糖尿病条件下。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Circ Res. 2023 年 8 月 29 日。doi：10.1161/CIRCRESAHA.123.323071。印刷前在线。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">背景：涉及 TNFα（肿瘤坏死因子 α）信号传导的免疫炎症途径的激活对于缺血性损伤后的血运重建和外周肌肉组织修复至关重要。尚不清楚。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">方法：通过激光多普勒成像和光片荧光显微镜监测突变小鼠永久股动脉结扎后的肌肉组织血运重建。TNFα介导的信号传导和CCL20（CC基序趋化因子配体20）-CCR6（CC趋化因子受体6）的作用使用骨髓移植、流式细胞术以及生化和分子生物学技术在体外和体内研究了新血管形成的轴。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> RESULTS: TNFα-mediated activation of tumor necrosis factor receptor TNFR (tumor necrosis factor receptor) 1 but not TNFR2 was found to be required for postischemic muscle tissue revascularization. Bone marrow-derived CCR6 <sup>+</sup> neutrophil granulocytes were identified as a previously undescribed TNFα-induced population of proangiogenic neutrophils, characterized by increased expression of VEGFA (vascular endothelial growth factor A). Mechanistically, postischemic activation of TNFR1 induced expression of the CCL20 in vascular cells and promoted translocation of the CCL20 receptor CCR6 to the cell surface of neutrophils, essentially conditioning VEGFA-expressing proangiogenic neutrophils for CCL20-dependent recruitment to sites of ischemia. Moreover, impaired revascularization of ischemic peripheral muscle tissue in diabetic mice was associated with reduced numbers of proangiogenic neutrophils and diminished CCL20 expression. Administration of recombinant CCL20 enhanced recruitment of proangiogenic neutrophils and improved revascularization of diabetic ischemic skeletal muscles, which was sustained by sequential treatment with fluvastatin. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> CONCLUSIONS: We demonstrate that site-specific activation of the CCL20-CCR6 axis via TNFα recruits proangiogenic VEGFA-expressing neutrophils to sites of ischemic injury for initiation of muscle tissue revascularization. The findings provide an attractive option for tissue revascularization, particularly under diabetic conditions.</p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/37641931/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230830120948&v=2.17.9.post6+86293ac">37641931</a> | DOI: <a href=https://doi.org/10.1161/CIRCRESAHA.123.323071>10.1161/CIRCRESAHA.123.323071</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:37641931</guid><pubDate> Tue, 29 Aug 2023 06:00:00 -0400</pubDate><dc:creator> Holger Lörchner</dc:creator><dc:creator> Laia Cañes Esteve</dc:creator><dc:creator> Maria Elisa Góes</dc:creator><dc:creator> Roxanne Harzenetter</dc:creator><dc:creator> Nathalie Brachmann</dc:creator><dc:creator> Praveen Gajawada</dc:creator><dc:creator> Stefan Günther</dc:creator><dc:creator> Nicolas Doll</dc:creator><dc:creator> Jochen Pöling</dc:creator><dc:creator> Thomas Braun</dc:creator><dc:date> 2023-08-29</dc:date><dc:source> Circulation research</dc:source><dc:title> Neutrophils for Revascularization Require Activation of CCR6 and CCL20 by TNFα</dc:title><dc:identifier> pmid:37641931</dc:identifier><dc:identifier> doi:10.1161/CIRCRESAHA.123.323071</dc:identifier></item><item><title> Concomitant Coronary Atheroma Regression and Stabilization in Response to Lipid-Lowering Therapy</title><link/> https://pubmed.ncbi.nlm.nih.gov/37640248/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230830120948&amp;v=2.17.9.post6+86293ac<description> CONCLUSIONS: Triple regression occurred in one third of AMI patients receiving high-intensity lipid-lowering therapy and was associated with alirocumab treatment, higher baseline lipid content and reduced cardiovascular events. </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> J Am Coll Cardiol. 2023 Aug 20:S0735-1097(23)06468-9. doi: 10.1016/j.jacc.2023.08.019. Online ahead of print.</p><p> <b>ABSTRACT</b> </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> BACKGROUND: The frequency, characteristics and outcomes of patients treated with high-intensity lipid-lowering therapy and showing concomitant atheroma volume reduction, lipid content reduction, and increase in fibrous cap thickness (ie, &quot;triple regression&quot;) are unknown. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> OBJECTIVES: This study was designed to investigate rates, determinants and prognostic implications of triple regression in patients presenting with acute myocardial infarction (AMI) and treated with high-intensity lipid-lowering therapy. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> METHODS: The PACMAN-AMI trial employed serial intravascular ultrasound, near-infrared spectroscopy, and optical coherence tomography to compare the effects of alirocumab vs. placebo in patients receiving high-intensity statin therapy. Triple regression was defined by the combined presence of percent atheroma volume (PAV) reduction, maximum lipid core burden index within 4 mm (maxLCBI <sub>4mm</sub> ) reduction, and minimal fibrous cap thickness (FCT) increase. Clinical outcomes at one-year follow-up were assessed. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> RESULTS: Overall, 84 (31.7%) patients showed triple regression (40.8% in the alirocumab group vs. 23.0% in the placebo group, p=0.002). On-treatment low-density lipoprotein cholesterol levels were lower in patients with vs. without triple regression (between-group difference -27.1 [-37.7 to -16.6] mg/dl, p&lt;0.001). Triple regression was independently predicted by alirocumab treatment (odds-ratio [OR] 2.83, 95% confidence interval [CI] 1.57-5.16, p=0.001) and a higher baseline maxLCBI <sub>4mm</sub> (OR 1.03, 95%CI 1.01-1.06, p=0.013). The composite clinical endpoint of death, myocardial infarction and ischemia-driven revascularization occurred less frequently in patients with vs. without triple regression (8.3% vs. 18.2%, p=0.04). </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> CONCLUSIONS: Triple regression occurred in one third of AMI patients receiving high-intensity lipid-lowering therapy and was associated with alirocumab treatment, higher baseline lipid content and reduced cardiovascular events.</p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/37640248/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230830120948&v=2.17.9.post6+86293ac">37640248</a> | DOI: <a href=https://doi.org/10.1016/j.jacc.2023.08.019>10.1016/j.jacc.2023.08.019</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:37640248</guid><pubDate> Mon, 28 Aug 2023 06:00:00 -0400</pubDate><dc:creator> Flavio G Biccirè</dc:creator><dc:creator> Jonas Häner</dc:creator><dc:creator> Sylvain Losdat</dc:creator><dc:creator> Yasushi Ueki</dc:creator><dc:creator> Hiroki Shibutani</dc:creator><dc:creator> Tatsuhiko Otsuka</dc:creator><dc:creator> Ryota Kakizaki</dc:creator><dc:creator> Thomas M Hofbauer</dc:creator><dc:creator> Robert-Jan van Geuns</dc:creator><dc:creator> Stefan Stortecky</dc:creator><dc:creator> Georgios Cm Siontis</dc:creator><dc:creator> Sarah Bär</dc:creator><dc:creator> Jacob Lønborg</dc:creator><dc:creator> Dik Heg</dc:creator><dc:creator> Christoph Kaiser</dc:creator><dc:creator> David Spirk</dc:creator><dc:creator> Joost Daemen</dc:creator><dc:creator> Juan Iglesias</dc:creator><dc:creator> Stephan Windecker</dc:creator><dc:creator> Thomas Engstrøm</dc:creator><dc:creator> Irene Lang</dc:creator><dc:creator> Konstantinos C Koskinas</dc:creator><dc:creator> Lorenz Räber</dc:creator><dc:date> 2023-08-28</dc:date><dc:source> Journal of the American College of Cardiology</dc:source><dc:title> Concomitant Coronary Atheroma Regression and Stabilization in Response to Lipid-Lowering Therapy</dc:title><dc:identifier> pmid:37640248</dc:identifier><dc:identifier> doi:10.1016/j.jacc.2023.08.019</dc:identifier></item><item><title> What Is a Normal Left Ventricular Ejection Fraction?</title><link/> https://pubmed.ncbi.nlm.nih.gov/37639509/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230830120948&amp;v=2.17.9.post6+86293ac<description> No abstract </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> <b>Circulation</b> . 2023 Aug 29;148(9):750-752. doi: 10.1161/CIRCULATIONAHA.123.065791. Epub 2023 Aug 28.</p><p> <b>NO ABSTRACT</b></p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/37639509/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230830120948&v=2.17.9.post6+86293ac">37639509</a> | DOI: <a href=https://doi.org/10.1161/CIRCULATIONAHA.123.065791>10.1161/CIRCULATIONAHA.123.065791</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:37639509</guid><pubDate> Mon, 28 Aug 2023 06:00:00 -0400</pubDate><dc:creator> Paul Heidenreich</dc:creator><dc:date> 2023-08-28</dc:date><dc:source> Circulation</dc:source><dc:title> What Is a Normal Left Ventricular Ejection Fraction?</dc:title><dc:identifier> pmid:37639509</dc:identifier><dc:identifier> doi:10.1161/CIRCULATIONAHA.123.065791</dc:identifier></item><item><title> Response by Ostadal and Belohlavek to Letter Regarding Article, &quot;Extracorporeal Membrane Oxygenation in the Therapy of Cardiogenic Shock: Results of the ECMO-CS Randomized Clinical Trial&quot;</title><link/> https://pubmed.ncbi.nlm.nih.gov/37639508/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230830120948&amp;v=2.17.9.post6+86293ac<description> No abstract </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> <b>Circulation</b> . 2023 Aug 29;148(9):804. doi: 10.1161/CIRCULATIONAHA.123.065358. Epub 2023 Aug 28.</p><p> <b>NO ABSTRACT</b></p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/37639508/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230830120948&v=2.17.9.post6+86293ac">37639508</a> | DOI: <a href=https://doi.org/10.1161/CIRCULATIONAHA.123.065358>10.1161/CIRCULATIONAHA.123.065358</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:37639508</guid><pubDate> Mon, 28 Aug 2023 06:00:00 -0400</pubDate><dc:creator> Petr Ostadal</dc:creator><dc:creator> Jan Belohlavek</dc:creator><dc:date> 2023-08-28</dc:date><dc:source> Circulation</dc:source><dc:title> Response by Ostadal and Belohlavek to Letter Regarding Article, &quot;Extracorporeal Membrane Oxygenation in the Therapy of Cardiogenic Shock: Results of the ECMO-CS Randomized Clinical Trial&quot;</dc:title><dc:identifier> pmid:37639508</dc:identifier><dc:identifier> doi:10.1161/CIRCULATIONAHA.123.065358</dc:identifier></item><item><title> Letter by Ferreira Regarding Article, &quot;Extracorporeal Membrane Oxygenation in the Therapy of Cardiogenic Shock: Results of the ECMO-CS Randomized Clinical Trial&quot;</title><link/> https://pubmed.ncbi.nlm.nih.gov/37639506/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230830120948&amp;v=2.17.9.post6+86293ac<description> No abstract </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> <b>Circulation</b> . 2023 Aug 29;148(9):803. doi: 10.1161/CIRCULATIONAHA.122.063622. Epub 2023 Aug 28.</p><p> <b>NO ABSTRACT</b></p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/37639506/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230830120948&v=2.17.9.post6+86293ac">37639506</a> | DOI: <a href=https://doi.org/10.1161/CIRCULATIONAHA.122.063622>10.1161/CIRCULATIONAHA.122.063622</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:37639506</guid><pubDate> Mon, 28 Aug 2023 06:00:00 -0400</pubDate><dc:creator> Jorge Ferreira</dc:creator><dc:date> 2023-08-28</dc:date><dc:source> Circulation</dc:source><dc:title> Letter by Ferreira Regarding Article, &quot;Extracorporeal Membrane Oxygenation in the Therapy of Cardiogenic Shock: Results of the ECMO-CS Randomized Clinical Trial&quot;</dc:title><dc:identifier> pmid:37639506</dc:identifier><dc:identifier> doi:10.1161/CIRCULATIONAHA.122.063622</dc:identifier></item><item><title> Stages of Dismantling Structural Racism in Medicine: A Focus on Medical Training</title><link/> https://pubmed.ncbi.nlm.nih.gov/37639505/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230830120948&amp;v=2.17.9.post6+86293ac<description> No abstract </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> <b>Circulation</b> . 2023 Aug 29;148(9):800-802. doi: 10.1161/CIRCULATIONAHA.123.066131. Epub 2023 Aug 28.</p><p> <b>NO ABSTRACT</b></p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/37639505/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230830120948&v=2.17.9.post6+86293ac">37639505</a> | DOI: <a href=https://doi.org/10.1161/CIRCULATIONAHA.123.066131>10.1161/CIRCULATIONAHA.123.066131</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:37639505</guid><pubDate> Mon, 28 Aug 2023 06:00:00 -0400</pubDate><dc:creator> Nisha Donthi</dc:creator><dc:creator> Catherine R Lucey</dc:creator><dc:creator> Michelle A Albert</dc:creator><dc:date> 2023-08-28</dc:date><dc:source> Circulation</dc:source><dc:title> Stages of Dismantling Structural Racism in Medicine: A Focus on Medical Training</dc:title><dc:identifier> pmid:37639505</dc:identifier><dc:identifier> doi:10.1161/CIRCULATIONAHA.123.066131</dc:identifier></item><item><title> Frailty and outcomes in heart failure patients from high-, middle- and low-Income countries</title><link/> https://pubmed.ncbi.nlm.nih.gov/37639487/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230830120948&amp;v=2.17.9.post6+86293ac<description> CONCLUSIONS: Frailty confers substantial incremental prognostic information to prognostic variables for predicting death and HF hospitalization. The relationship between frailty and these outcomes is consistent across countries at all income levels. </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Eur Heart J. 2023 Aug 28:ehad595. doi: 10.1093/eurheartj/ehad595. Online ahead of print.</p><p> <b>ABSTRACT</b> </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> BACKGROUND AND AIMS: There is little information on the incremental prognostic importance of frailty beyond conventional prognostic variables in heart failure (HF) populations from different country income levels. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> METHODS: 3429 adults with HF (age 61±14 years, 33% women) from 27 high-, middle- and low-income countries were prospectively studied. Baseline frailty was evaluated by the Fried index, incorporating handgrip strength, gait speed, physical activity, unintended weight loss and self-reported exhaustion. Mean left ventricular ejection fraction was 39±14% and 26% had New York Heart Association (NYHA) class III/IV symptoms. Participants were followed for a median (25th-75th percentile) 3.1 (2.0-4.3) years. Cox proportional hazards models for death and HF hospitalization adjusted for country income level; age; sex; education; HF etiology; left ventricular ejection fraction; diabetes; tobacco and alcohol use; NYHA functional class; HF medication use; blood pressure; hemoglobin, sodium and creatinine concentrations were performed. The incremental discriminatory value of frailty over and above the MAGGIC risk score was evaluated by the area under the receiver-operating characteristic curve. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> RESULTS: At baseline, 18% of participants were robust, 61% pre-frail and 21% frail. During follow-up, 565 (16%) participants died and 471 (14%) were hospitalized for HF. Respective adjusted hazard ratios [HRs (95% CI)] for death among the prefrail and frail were 1.59 (1.12-2.26) and 2.92 (1.99-4.27). Respective adjusted HRs (95% CI) for HF hospitalization were 1.32 (0.93-1.87) and 1.97 (1.33-2.91). Findings were consistent among different country income levels and by most subgroups. Adding frailty to the MAGGIC risk score improved the discrimination of future death and HF hospitalization. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> CONCLUSIONS: Frailty confers substantial incremental prognostic information to prognostic variables for predicting death and HF hospitalization. The relationship between frailty and these outcomes is consistent across countries at all income levels.</p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/37639487/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230830120948&v=2.17.9.post6+86293ac">37639487</a> | DOI: <a href=https://doi.org/10.1093/eurheartj/ehad595>10.1093/eurheartj/ehad595</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:37639487</guid><pubDate> Mon, 28 Aug 2023 06:00:00 -0400</pubDate><dc:creator> Darryl P Leong</dc:creator><dc:creator> Philip Joseph</dc:creator><dc:creator> John JV McMurray</dc:creator><dc:creator> Jean Rouleau</dc:creator><dc:creator> Aldo P Maggioni</dc:creator><dc:creator> Fernando Lanas</dc:creator><dc:creator> Sanjib K Sharma</dc:creator><dc:creator> Julio Núñez</dc:creator><dc:creator> Bishav Mohan</dc:creator><dc:creator> Ahmet Celik</dc:creator><dc:creator> Jabir Abdullakutty</dc:creator><dc:creator> Okechukwu S Ogah</dc:creator><dc:creator> Lisa M Mielniczuk</dc:creator><dc:creator> Kumar Balasubramanian</dc:creator><dc:creator> Tara McCready</dc:creator><dc:creator> Alex Grinvalds</dc:creator><dc:creator> Salim Yusuf</dc:creator><dc:creator> P Joseph</dc:creator><dc:creator> G-CHF Investigators</dc:creator><dc:date> 2023-08-28</dc:date><dc:source> European heart journal</dc:source><dc:title> Frailty and outcomes in heart failure patients from high-, middle- and low-Income countries</dc:title><dc:identifier> pmid:37639487</dc:identifier><dc:identifier> doi:10.1093/eurheartj/ehad595</dc:identifier></item><item><title> Third generation PCSK9-Inhibitors</title><link/> https://pubmed.ncbi.nlm.nih.gov/37639486/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230830120948&amp;v=2.17.9.post6+86293ac<description> No abstract </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Eur Heart J. 2023 Aug 28:ehad566. doi: 10.1093/eurheartj/ehad566. Online ahead of print.</p><p> <b>NO ABSTRACT</b></p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/37639486/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230830120948&v=2.17.9.post6+86293ac">37639486</a> | DOI: <a href=https://doi.org/10.1093/eurheartj/ehad566>10.1093/eurheartj/ehad566</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:37639486</guid><pubDate> Mon, 28 Aug 2023 06:00:00 -0400</pubDate><dc:creator> Ulrich Laufs</dc:creator><dc:creator> Matthias Blüher</dc:creator><dc:creator> Berend Isermann</dc:creator><dc:date> 2023-08-28</dc:date><dc:source> European heart journal</dc:source><dc:title> Third generation PCSK9-Inhibitors</dc:title><dc:identifier> pmid:37639486</dc:identifier><dc:identifier> doi:10.1093/eurheartj/ehad566</dc:identifier></item></channel></rss>